Derisking Complex CMC Development
Accelerating Series A–C biotechs, BLA, NDA, 505(b)(2) and ANDA programs with the same rigor that delivered dozens of Pfizer programs, and one of industry’s first real-time release solid oral NDA
Fluent in Global Regulatory Defense
Leveraging QbD, deep scientific know-how, statistical optimization, and advanced modeling to deliver robust dose forms.
Learn more →Overcoming formulation, delivery, stability & combination product challenges for high-value liquid and lyophilized assets.
Learn more →Amplifying resource ROI while compressing development timelines. Focusing strictly on the value drivers that yield superior results.
Learn more →Mitigating organizational risk by orchestrating compliant facility exits and workforce transitions through rigorous change management.
Learn more →